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Major depression (MD) is one of the most common psychiatric disorders, severely
affecting the quality of life of millions of people worldwide. Despite the availability of
several classes of antidepressants, treatment efficacy is still very variable and many
patients do not respond to the treatment. Clomipramine (CMI), a classical and widely
used antidepressant, shows widespread interindividual variability of efficacy, while the
environmental factors contributing to such variability remain unclear. We investigated
whether chronic stress modulates the bio-distribution of CMI, and as a result the behavioral
response to CMI treatment in a mouse model of chronic social defeat stress (CSDS). Our
results show that stress exposure increased anxiety-like and depressive-like behaviors and
altered the stress response. Chronic defeat stress furthermore significantly altered CMI
bio-distribution. Interestingly, CMI bio-distribution highly correlated with anxiety-like and
depressive-like behaviors only under basal conditions. Taken together, we provide first
evidence demonstrating that chronic stress exposure modulates CMI bio-distribution and
behavioral responses. This may contribute to CMI’s broad interindividual variability, and is
especially relevant in clinical practice.
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INTRODUCTION
Major depression (MD) is a prevalent and debilitating disorder,
affecting an estimated 350 million people worldwide (World
Health Organisation, 2012). Despite the availability of
several classes of antidepressants, symptom relief in the
treatment of depression is often incomplete and highly
variable between individuals (Labermaier et al., 2013).
Currently, dose optimization for effective treatment of
depression is achieved only by means of trial and error.
Identification of early predictors of treatment response,
including both genetic and environmental factors, is therefore
an important step in optimizing the current treatment options
for MD.
Stress is a major risk factor for depression, and dysregula-
tion of the HPA axis as well as heightened stress reactivity are
among the most consistent features in patients suffering from
MD (Holsboer, 2000; Gallagher et al., 2007; Holsboer and Ising,
2010). Remission from MD is furthermore associated with the
normalization of the HPA axis (Holsboer, 2000; Ising et al., 2007).
However, there is a paucity of research exploring the effects of
stress exposure on the therapeutic efficacy of various commonly
used antidepressants.
Clomipramine (CMI), a tricyclic antidepressant, is commonly
prescribed to treat depression, obsessive compulsive disorder,
and panic disorders (Trimble, 1990). There is a broad interindi-
vidual variation in its efficacy, which is characteristic of many
tricyclic antidepressants. The most well recognized processes
contributing to interindividual variation in patient responses
are pharmacokinetic in nature, influencing drug metabolism
and drug partitioning (Shimoda et al., 1995; Vandel et al.,
2004). Significant differences in the metabolic ratio have been
described between patients who suffer from CMI side effects
and those who present good tolerance to CMI. Importantly,
the measurement of CMI and desmethylclomipramine (DCMI),
an active metabolite, in the serum has been shown to improve
dose optimization, and subsequently the therapeutic outcome to
CMI treatment in patients (Mavissakalian et al., 1990; Noguchi
et al., 1993; Marcourakis et al., 1999). For example, improved
therapeutic outcome is associated with higher serum levels of
CMI and DCMI as well as a higher metabolic ratio of CMI
to DCMI (Szegedi et al., 1996). To-date, diverging pharmacoki-
netic factors and clinical responses to CMI observed amongst
patients have been largely attributed to genetic factors (Basu
et al., 2004; Kirchheiner et al., 2004). Identification of environ-
mental factors that predict drug efficacy and/or patient response
remains largely elusive despite the potential clinical implica-
tions. In particular, it is unknown whether chronic stress is
able to actively modulate CMI metabolism or its distribution
from the plasma to the brain, and potentially the therapeu-
tic response to CMI treatment. Here, we combined a val-
idated mouse model of chronic social defeat stress (CSDS)
with CMI treatment in order to test whether stress is able
to alter CMI metabolism, tissue partitioning, and treatment
efficacy.
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METHODS
ANIMALS AND ANIMAL HOUSING
Twelve-week old male C57BL/6 mice (Charles River Laboratories,
Maastricht, Netherlands) were maintained under standard lab
conditions (12:12 h light/dark cycle, controlled temperature (22
+/− 2◦C) and humidity (55+/− 5%), and ad libitum access to
food and water). Mice were singly-housed and acclimated to the
room for 10 days before the experimental onset. The experiments
were carried out in accordance with the European Communities’
Council Directive 2010/63/EU. All efforts were made to minimize
animal suffering during the experiments. The protocols were
approved by the committee for the Care and Use of Laboratory
animals of the Government of Upper Bavaria, Germany.
EXPERIMENTAL DESIGN
Mice were randomly assigned to 2 × 2 groups (control vehicle
(n = 12), control CMI (n = 12), chronic stress vehicle (n = 12), and
chronic stress CMI (n = 11)) counterbalanced by body weight.
Clomipramine was administered orally through drinking water
(0.12 mg/ml) from the first day of the stress procedure (day 1)
until the animals were sacrificed (day 22). An open field (OF)
test and forced swim test (FST) were performed on day 16 and
day 18, respectively in order to assess CMI efficacy. We were
mindful of the behavioral testing order, beginning with the least
invasive test before testing more invasive assays (McIlwain et al.,
2001; Paylor et al., 2006). Therefore the OF test was carried out
before the FST and there was one full day of rest between the
two tests. Body weight was measured daily and fluid intake was
measured twice weekly throughout the entire experimental time-
course. Behavioral testing and animal sacrifice always occurred
in the morning at approximately the same time so that levels of
metabolites measured at the time of sacrifice are representative of
levels at the time of testing.
CHRONIC SOCIAL DEFEAT STRESS PROCEDURE
The CSDS paradigm lasted for 21 days and was conducted as
described previously (Wagner et al., 2011, 2012). Briefly, exper-
imental mice were placed in the home cage of a dominant CD1
resident mouse. Interaction between the mice was permitted until
the experimental mouse was attacked and defeated by the CD1
aggressor. Mice were subsequently separated by a wire mesh
divider that prevented physical contact but maintained sensory
contact for 24 h. Each day, for 21 days, the procedure was repeated
with a different, unfamiliar CD1 aggressor mouse. Both control
and stress animals were handled daily during the course of the
stress procedure.
OPEN FIELD
Mice were placed in one corner of a 50 cm × 50 cm × 40 cm
arena. Thirty-minute trials were video-recorded by an overhead
camera and analyzed using the automated video tracking software
ANYmaze 4.9 (Stoelting, Wood Dale, IL, USA). The arena was
cleaned with water at the beginning of testing and in between
animals. Total distance traveled and time spent in the OF center
was measured. For analysis of time spent in the center of the arena,
a center zone was virtually defined as a 25 cm × 25 cm central
square.
FORCED SWIM TEST
Mice were placed in a 2 L glass beaker filled with room-
temperature (22 ± 1◦C) water to a height of 15 cm so that the
mouse could neither touch the bottom nor escape. The test lasted
6 min and was later analyzed by an experienced experimenter,
blind to the experimental group. The first 2 min were designated
a habituation period, and therefore time spent immobile and
time spent struggling in the final 4 min of the test were scored
(Castagne et al., 2009).
ACUTE STRESS RESPONSE
The FST additionally served as an acute stressor to examine
the stress response. The stress response was performed as pre-
viously described (Wagner et al., 2012; Balsevich et al., 2014;
Santarelli et al., 2014). Briefly, at the conclusion of the FST,
animals were towel-dried and returned to their home cages to
recover. At 30-min (stress response) and 90-min (stress recov-
ery) after the onset of the FST, blood samples were taken
by tail cut (Fluttert et al., 2000). The 30-min time point
was chosen based on previous data indicating a near max-
imal response of the HPA axis at this time (Droste et al.,
2008). Samples were collected in EDTA-coated microcentrifuge
tubes (Kabe Labortechnik, Germany) and kept on ice until
all samples were centrifuged at 8000 rpm at 4◦C for 15 min.
Plasma was collected and stored at −20◦C. Plasma corticos-
terone levels were determined by radioimmunoassay using a
commercially available kit (MP Biomedicals Inc.; sensitivity
12.5 ng/ml).
TISSUE COLLECTION AND PROCESSING
On day 22 of the experimental timeline, mice were anesthetized
with Isofluorane and then immediately sacrificed by decapitation.
Basal trunk blood was collected and subsequently processed (as
described above). Brains were removed, snap-frozen, and stored
at −80◦C until use. Adrenal glands were removed, pruned from
fat, and weighed.
ANTIDEPRESSANT METABOLITE ASSESSMENT
Mice brains were weighed and then homogenized in the fivefold
volume phosphate buffered saline (PBS), containing “Complete
Protease Inhibitor Cocktail Tablets” (Roche, Penzberg, Germany)
using a Dispomix Drive (Medic Tools AG, Zug, Switzerland).
The blood plasma and the brain homogenates were ana-
lyzed using the combined high-performance liquid chromatogra-
phy/mass spectrometry (HPLC/MS-MS) technique. Analysis was
performed using an Agilent 1100 Series (Agilent, Waldbronn,
Germany) liquid chromatograph, which was interfaced to the ESI
source of an Applied Biosystems API 4000 (ABSciex, Darmstadt,
Germany) triple quadrupole mass spectrometer. All samples were
prepared using Ostro protein precipitation and phospholipid
removal plates (Waters, Eschborn, Germany).
Deuterated CMI (CMI-D3) was used as internal standard.
Chromatography was accomplished using an gradient elution
in a Accucore RP-MS 2.6 µm column (2.1 × 50 mm, Thermo
Scientific, Dreieich, Germany) at a flow rate of 0.3 ml/min and
30◦C.
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The composition of eluent A was methanol with 10 mM
ammonium formate with 0.1% formic acid and water with
10 mM ammonium formate with 0.1% formic acid as eluent B.
The gradient was 0–0.5 min 20% A, 0.5–2 min 20–90% A,
1 min held at 90% A, 3–3.5 min 90–20% A and 3.5–8 min 20%
A. The total run time was 8 min and the injection volume was
5 µl.
The retention time for CMI, DCMI and CMI-D3 were 4.9 min,
4.9 min and 4.9 min, respectively. The ion source was oper-
ated in the positive mode at 500◦C, and multiple reaction
monitoring (MRM) collision-induced dissociation (CID) were
performed using nitrogen gas as the collision gas. The colli-
sion energy was set to 27 V, 33 V and 27 V for CMI, DCMI
and CMI-D3, respectively. The transitions monitored during
analysis were m/z 315 → 86 for CMI, m/z 301 → 72 for
DCMI and 318 → 89 for CMI-D3. The detection limit for
CMI in plasma was 5 ng/ml and 3 ng/g wet weight in brain
tissue and 2.5 ng/ml and 3 ng/g wet weight in brain tissue for
DCMI.
DATA ANALYSIS
All variables were evaluated using IBM SPSS Statistics 18 soft-
ware (IBM SPSS Statistics, IBM, Chicago, IL, USA). Data
were analyzed by 2-way ANOVA for significant effects of
treatment and stress. Where the initial test yielded a sig-
nificant interaction, a Bonferroni post hoc test was applied.
Where there was only one grouping variable, independent
Student’s T-test were used. Finally, correlations were ana-
lyzed with the Pearson product-moment test. Statistical signif-
icance was set at p < 0.05. Data are presented as mean ±
S.E.M.
RESULTS
BODY WEIGHT AND FLUID INTAKE
Body weight gain from the onset of CSDS/treatment exposure
until sacrifice was not significantly affected by either stress or
CMI treatment. There was a significant effect of stress on fluid
consumption (stress: F(1,44) = 133.195, p < 0.001) in which
stress significantly increased daily fluid intake. There was how-
ever no effect of CMI treatment on fluid intake. Mice exposed
to CSDS therefore received a higher dose of CMI compared
to control animals receiving CMI treatment (T(16,9) = −9.368,
p< 0.001).
BEHAVIOR AND NEUROENDOCRINE PARAMETERS
Stress exposure resulted in increased anxiety-like behavior, as
demonstrated by the reduced number of entries into the cen-
ter (stress: F(1,44) = 7.563, p = 0.009) and a trend towards
reduced center time in the OF test (stress: F(1,44) = 3.478,
p = 0.069). Although there was no significant treatment
× stress interaction for either OF center time or center
entries, the reduced center time and center entries in the
OF test on account of CSDS, appear to be largely mediated
by the CMI-treated cohort (Figure 1A). Stress additionally
FIGURE 1 | Effects of CMI treatment and/or chronic defeat stress on
behavioral and physiological parameters in mice. (A) The number of
entries into the center and the time spent in the center of a 30-min open field
test. (B) The time spent struggling and the time spent immobile in the forced
swim test. (C) Basal morning corticosterone levels as well as response
corticosterone levels and recovery corticosterone levels 30 min and 90 min
following an acute stressor (FST), respectively. (D) Relative adrenal gland
weight. All data were analyzed by two-way ANOVA and are represented as
the mean +/− S.E.M. ## p < 0.01, ### p < 0.001, + p < 0.05; # significant
stress effect and + significant CMI treatment effect.
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tended to reduce total distance traveled in the OF (stress:
F(1,44) = 3.024, p = 0.089). Likewise heightened depressive-
like behaviors resulted from CSDS, shown in the FST as a
reduction in time spent struggling (stress: F(1,40) = 6.054,
p = 0.018) and an increase time spent immobile (stress:
F(1,44) = 22.211, p < 0.001; Figure 1B). Stress furthermore
enhanced the stress response as shown by elevated basal
(F(1,44) = 7.649, p = 0.008), response (F(1,44) = 25.136, p< 0.001),
and recovery (F(1,42) = 6.590, p = 0.014) corticosterone lev-
els (Figure 1C). By contrast, CMI had no main effect on any
of the parameters (center time, center entries, total distance)
measured in the OF test or on corticosterone levels. There
was a trend indicating that CMI treatment reduced the time
spent immobile (CMI: F(1,44) = 3.413, p = 0.071) in the FST
(Figure 1B). Finally stress significantly increased adrenal size
(stress: (F(1,43) = 100.902, p < 0.001) whereas CMI treatment led
to reduced adrenal size (treatment: (F(1,43) = 4.768, p = 0.034;
Figure 1D).
CMI AND DCMI LEVELS
Clomipramine and DCMI levels were measured in the plasma
and the brain and the absolute values are presented in
Table 1. Briefly, stress exposure significantly lowered absolute
levels of CMI in the brain (T(11,7) = 2.302, p = 0.041), but
stress did not significantly affect the levels of CMI in the
plasma or DCMI levels in the plasma and brain. Metabolic
ratios and partitioning ratios were investigated as an index
of CMI pharmacokinetics, thereby also controlling for the
observed differences in fluid intake. Assessment of the metabolic
ratios (defined as the ratio of CMI to DCMI) revealed an
effect of stress. The metabolic ratios were significantly low-
ered on account of CSDS in the plasma (T(21) = 3.981,
p = 0.001) and in the brain (T(16,41) = 6.600, p < 0.001;
Figure 2A). In order to assess whether tissue distribution of
CMI/DCMI was affected by stress, we treated tissue and CSDS
as independent variables. Significant effects of stress and tis-
sue were detected (stress: F(1,43) = 57.905, p < 0.001; tissue:
F(1,43) = 4.968, p = 0.031). Importantly, a significant interac-
tion was also detected to reveal that only under control con-
ditions was the CMI/DCMI ratio significantly higher in the
brain compared to the plasma (stress × tissue: F(1,43) = 5.343,
p = 0.026). Regardless, control animals presented a higher
Table 1 | Absolute concentrations of CMI and DCMI in plasma (ng/ml)
and brain (ng/g) tissue.
Condition Measurement Mean +/− S.E.M. Unit
Control Absolute CMI plasma 24.2 +/− 5.5 ng/ml
CSDS 14.3 +/− 1.4
Control Absolute DCMI plasma 4.3 +/− 0.8 ng/ml
CSDS 6.3 +/− 1.3
Control Absolute CMI brain 224.3 +/− 59.1 ng/g
CSDS 86.2 +/− 10.4
Control Absolute DCMI brain 23.4 +/− 5.6 ng/g
CSDS 39.2 +/− 8.4
Data are represented as the mean +/− S.E.M.
FIGURE 2 | Stress-induced modulatory effects on CMI
pharmacokinetics. (A) Clomipramine metabolic ratio in the plasma and
brain. (B) Partitioning ratio for CMI and its active metabolite DCMI. Data
were analyzed by Student’s T -tests for stress effects and by two-way
ANOVA for tissue and stress effects on tissue distribution. All data are
represented as the mean +/− S.E.M. ∗∗p < 0.01, # p < 0.05, ## p < 0.01,
### p < 0.001; # significant stress effect and * significant tissue effect.
CMI/DCMI ratio in both plasma and brain compared to stressed-
animals.
To measure brain uptake of CMI and DCMI, the partition-
ing ratio (defined as the brain-to-plasma concentration) was
calculated. Chronic social defeat stress significantly decreased
the partitioning ratio for CMI (T(21) = 3.663, p = 0.001),
whereas significantly increased the partitioning ratio for DCMI
(T(21) =−2.460, p = 0.023; Figure 2B).
CORRELATIONS
The Pearson product-moment test was used to describe the rela-
tionship between CMI bio-distribution and behavioral responses.
The analyses were subdivided by stress condition to account
for the main stress effects on both CMI bio-distribution and
behavioral readouts, which would bias the relationship. Under
basal conditions, the CMI/DCMI metabolic ratio for both the
plasma and brain negatively correlated to the time spent immobile
(floating) in the FST (plasma: r = −0.693, p = 0.018; brain:
r =−0.643, p = 0.024; Figures 3A,B). This correlation was absent
under stress conditions. Finally, the DCMI partitioning ratio pos-
itively correlated to the time spent immobile (r = 0.610, p = 0.035;
Figure 3C) under stress, but not under control conditions.
DISCUSSION
Tricyclic antidepressants, and in particular CMI, are known
to display a broad range of inter-individual variation result-
ing from differences in CMI pharmacokinetics (Shimoda et al.,
1995; DUAG, 1999; Vandel et al., 2004). Regardless, the effects
of environmental factors, and specifically chronic stress, on
CMI metabolism or its distribution remain largely unknown.
For this purpose, we chose to examine the effects of stress
on CMI bio-distribution and treatment efficacy in an animal
model of CSDS, which is accepted as a model for clinical
features of depression (Savignac et al., 2011). In agreement
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FIGURE 3 | Correlational analysis between the plasma (A) and brain
(B) metabolic ratio and time spent immobile in the FST. (C) Relationship
between DCMI partitioning ratio and time spent immobile in the FST. The
mean of the water-treated control group is shown as a dashed line and the
corresponding S.E.M. is shaded in gray. Correlations were analyzed with the
Pearson product-moment test. Statistical significance was set at p < 0.05.
with previous studies, CSDS resulted in increased anxiety-like
and depressive-like behaviors indicated in the OF and FST,
respectively. Stress furthermore resulted in an enhanced stress
response. There was however no improvement in anxiety-
like behaviors, depressive-like behaviors, or stress reactivity
on account of CMI treatment per se. Nevertheless stress sig-
nificantly altered CMI bio-distribution under basal condi-
tions, which in turn predicted anxiety-like and depressive-like
behaviors.
Variations in antidepressant pharmacokinetics and serum
drug concentrations are considered to be an important reflection
of patient treatment outcomes (Noguchi et al., 1993; DUAG,
1999). In order to control for differences in dosage between
stress conditions, we evaluated relative values, namely metabolic
ratios and partitioning ratios, rather than absolute values. Inter-
estingly, although the mice in the stress group consumed more
CMI compared to control animals, the absolute values of CMI
assessed in the plasma and brain were similar or even lower
in the mice that underwent CSDS compared to controls. The
same is true for absolute values of DCMI. Therefore CSDS led
to lower absolute brain CMI levels despite an increased CMI
dosage.
In order to establish whether stress was able to modulate
CMI efficacy, we examined CMI and DCMI levels and bio-
distribution. The data suggest that chronic stress affects overall
drug levels in the brain and the periphery by promoting exten-
sive metabolism of CMI to DCMI. Interestingly, stress expo-
sure appeared to have a stronger effect in the brain compared
to the periphery. For example, under control conditions, the
metabolic ratio was significantly higher in the brain compared
to the plasma, whereas stress exposure led to comparable brain
and plasma metabolic ratios. In clinical practice, therapeutic
drug monitoring (TDM) is performed for optimal individualized
antidepressant drug therapy in order to adjust for variations
in drug absorption, metabolism, and elimination. Of course,
TDM is performed on plasma or serum samples, and conse-
quently practitioners are blind to drug concentrations in the
brain. Previous findings showed that steady state concentrations
of CMI and DCMI strongly reflect brain concentrations in rats,
and support the use of TDM for dose optimization (Weigmann
et al., 2000). Stress exposure may thus be an important factor
to consider for dose optimization as it modulates CMI drug
metabolism as well as the relationship between plasma and
brain levels. In this regard, life history assessments in psychi-
atric practice may be a critical prerequisite for individualized
intervention.
We further investigated the effects of chronic stress expo-
sure on the drug distribution for CMI and DCMI by eval-
uating the partitioning ratio. Our data agree with previous
findings indicating that the levels of CMI and DCMI are
significantly greater in the brain compared to the plasma
(Nagy, 1977; Kurata et al., 1986; Fujita et al., 1991; Sgaragli
et al., 1995; Weigmann et al., 2000). Interestingly, CSDS sig-
nificantly lowered the relative amount of CMI in the brain,
whereas significantly increased the relative amount of DCMI.
The differential effect of stress exposure on the partitioning
ratio for CMI and DCMI suggests that DCMI is preferen-
tially sequestered in the brain on account of stress exposure,
which may further influence the differential efficacy of CMI
treatment.
Next, we explored whether the differential metabolic and par-
titioning ratios are able to predict the behavioral and endocrine
treatment response. We performed the analyses separately for
control and stress conditions, as otherwise the strong effects of
stress on both behavioral responses and CMI bio-distribution
would bias the correlation. Our data indicate that the metabolic
ratios under control conditions are predictive for depressive-
like behavior observed in the FST (Figures 3A,B). Interest-
ingly, this association is lost under stress conditions. The CSDS
cohort presented reduced variability within both the behav-
ioral responses as well as the metabolic ratios, highlighting the
great extent to which stress is able to impact both depressive-
like behavior and CMI metabolism. In this context, the ability
to predict behavioral responses by examining plasma or brain
metabolic ratios may be rendered obsolete in a situation of
chronic stress, whereby stress may produce a ceiling effect. Nev-
ertheless, the observed associations between the metabolic ratios
and FST behavioral readouts in control mice suggests that there
is in fact a treatment effect, which depends, in part, on CMI
metabolism.
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The correlational analyses also revealed that the partitioning
of DCMI between brain and plasma is an important indicator
of treatment efficacy under conditions of chronic stress, which
is in sharp contrast to the associations related to the metabolic
ratios whereby behavioral responses were exclusively related
to CMI metabolism under control conditions. This again has
clinical significance as either the metabolic ratio or partitioning
ratio may be an indicator of treatment efficacy in control and
stress conditions, respectively. The differences may furthermore
underlie differences in activity between CMI and DCMI, given
CMI is a stronger inhibitor of serotonin reuptake whereas DCMI
is a stronger inhibitor of norepinephrine re-uptake (Balant-
Gorgia et al., 1991). Further studies are required to concretely
assess the relationship between treatment response and CMI
metabolism and bio-distribution, and extend the current findings
to other classes of antidepressants. We acknowledge that our study
design has its limitations. Future studies are required in order
to identify the molecular underpinnings governing the effects
of stress on CMI pharmacokinetics. Plausible stress-induced
mechanisms resulting in such alterations include the ability of
stress to modulate the distribution of multi-drug transporter
proteins at the blood brain barrier and thus drug entry into
the brain (de Klerk et al., 2010) and/or modulate the activity
of CYP2D6 (the enzyme responsible for CMI metabolism), and
thus drug bioavailability (Daskalopoulos et al., 2012). Regardless,
our study clearly shows a strong effect of stress exposure on CMI
metabolic ratios and tissue partitioning, and further suggests that
this subsequently regulates treatment responsiveness.
CONCLUSION
Collectively, our data illustrate that improved behavioral
responses are associated with a higher metabolic ratio of CMI
to DCMI, which is in agreement with the situation observed
in patients (Dencker and Nagy, 1979; Szegedi et al., 1996).
Stress modulates CMI metabolic ratios, which has important
implications for dose optimization. To our knowledge, this
is the first direct demonstration that chronic stress exposure
modulates CMI metabolic ratios and tissue partitioning and
subsequently treatment efficacy. This may contribute to CMI’s
broad interindividual variability and the widespread efficacy of
CMI. Our data strongly promote the implementation of TDM
and life history assessments as essential steps in clinical prac-
tice to guide individualization of medication (Hiemke et al.,
2011), which may likewise indirectly reflect the patient’s stress
reactivity.
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